Author:
Molina Jean-Michel,Ward Douglas,Brar Indira,Mills Anthony,Stellbrink Hans-Jürgen,López-Cortés Luis,Ruane Peter,Podzamczer Daniel,Brinson Cynthia,Custodio Joseph,Liu Hui,Andreatta Kristen,Martin Hal,Cheng Andrew,Quirk Erin
Subject
Virology,Infectious Diseases,Immunology,Epidemiology
Reference16 articles.
1. Antiviral activity, safety, and pharmacokinetics of bictegravir as 10-day monotherapy in HIV-1-infected adults;Gallant;J Acquir Immune Defic Syndr,2017
2. Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile;Tsiang;Antimicrob Agents Chemother,2016
3. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial;Gallant;Lancet,2017
4. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial
Cited by
130 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献